Endo International (NASDAQ:ENDP) (TSE:ENL) announced its quarterly earnings results on Tuesday. The company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.15, Briefing.com reports. The business had revenue of $768.64 million for the quarter, compared to analyst estimates of $762.29 million. Endo International had a negative net margin of 126.97% and a positive return on equity of 66.98%. The company’s revenue was down 38.1% on a year-over-year basis. During the same quarter last year, the firm earned $1.77 EPS. Endo International updated its FY18 guidance to $2.15-2.55 EPS.
Shares of Endo International (NASDAQ ENDP) opened at $6.81 on Wednesday. Endo International has a 52 week low of $5.77 and a 52 week high of $14.45. The company has a debt-to-equity ratio of 10.78, a quick ratio of 0.86 and a current ratio of 1.08. The company has a market cap of $1,527.46, a PE ratio of -0.30, a P/E/G ratio of 2.39 and a beta of 0.29.
A number of brokerages have recently weighed in on ENDP. Gabelli lowered shares of Endo International from a “buy” rating to a “hold” rating in a research note on Wednesday. Canaccord Genuity set a $7.00 target price on shares of Endo International and gave the company a “hold” rating in a research note on Tuesday. Oppenheimer reaffirmed a “hold” rating on shares of Endo International in a research note on Tuesday. Cantor Fitzgerald set a $7.00 target price on shares of Endo International and gave the company a “hold” rating in a research note on Tuesday. Finally, Barclays cut their target price on shares of Endo International from $15.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Friday, February 23rd. Three investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Hold” and an average price target of $10.32.
ILLEGAL ACTIVITY WARNING: “Endo International (ENDP) Issues Earnings Results” was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3225656/endo-international-endp-issues-quarterly-earnings-results.html.
Endo International Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.